Refinancing As Well As Merging Financial Debt

California it isn’t just ideal express to live, within get in terms of getting one­s home, for the reason that home stocks enhance appreciatively. If you are a home owner inside State involving California, look at taking advantage of the worth positioned on the home to obtain the dollars a person needed. You ought to [...]

Source: http://www.legaldebthelponline.com/2011/10/25/refinancing-as-well-as-merging-financial-debt/

debt elimination calculator debt elimination programs debt fix debt free america

Debt Management Companies Can Help You in Negotiating Your Debts

[WizardRSS: unable to retrieve full-text content]

A professional debt management company has years of hands on experience in dealing with the creditors and the debt collection services. Mostly an intervention by a debt management company is seen positively by your creditors or debt collection services as they will understand that you are acknowledging your debt problems and are seeking professional help to resolve them.

Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement

Source: http://ezinearticles.com/6655875

american debt settlement american debt solutions bad debt collection bad debt mortgage

The Credit Card Valve Is NOT Easy to Control

[WizardRSS: unable to retrieve full-text content]

As a result of these challenging economic times, many Americans exceed their credit card's maximum line of credit thus triggering the default 29.9% interest rate inflaming an already daunting financial problem. Most credit card companies take no responsibility because they believe the card holder has fallen into a trap largely of their own making. At least when the mob was in the loan shark business, their victims didn't have to put up with that kind of self-righteous nonsense. This article details how the banks and credit card companies prey on the poorest of us and offers simple strategies on avoiding this almost criminal act.

Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement

Source: http://ezinearticles.com/6652611

christian debt relief clear your debt cnn debt calculator consolidate my debt

Biotech Blunder Turned 20% Overnight Gain

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Sometimes even when things go wrong, they can still work out in your favor. When Exelixis (Nasdaq: EXEL  ) announced a delay in presenting the results of its phase 3 trial testing cabozantinib in patients with advanced medullary thyroid cancer, I proposed three possible reasons for the delay:

  • Patients taking cabozantinib are living longer than expected.
  • Patients taking placebo are living longer than expected.
  • Both.

Turns out none of them were the case -- at least not when looking at the median progression free survival, a measurement of how long it takes for the tumor to start growing again.

Exelixis was looking for an eight-month median progression free survival for the placebo arm and hoping for at least a 75% increase for patients taking cabozantinib, so at least 14 months. The results announced today pegged the median progression free survival at just 4.0 months for the placebo and 11.2 months for patients taking cabozantinib. Nearly tripling placebo's median progression free survival is a solid win for cabozantinib -- there's less than a 0.01% chance that it happened randomly -- but the results were still nowhere near what Exelixis expected.

The estimate being off shouldn't be a big surprise; the median survival estimate was just a guess. Exelixis tightened the enrollment criteria in the phase 3 trial to include only patients with progressing disease, so the earlier phase 1/2 trial, which included less severe patients, wasn't much help in estimating how long it would take for the more-advanced patients to progress.

Medians vs. averages
But then why did the trial take longer than expected if the median progression-free survival was actually shorter than the estimate? We'll have to head back to third-grade math to explain this one.

The median of a group of numbers is the one in the middle. Unlike an average -- where you add up all the numbers and divide by the number of members in the group -- the numbers at the extreme don't matter for a median. So the median of 11,12,13,14,15 is 13, but the median of 11,12,13,14,30 is also 13.

Exelixis only released top-line data, but the simple explanation is that there are some patients in one or both of the groups that are outliers, taking a lot longer than the median to progress. Since the trial could only be stopped after a certain number of progression free survival events, the outliers delayed the readout even though they didn't affect the median.

Houston, do we have a problem?
If the outliers are predominately in the arm that got cabozantinib, there's likely a subset of patients that are responding well to cabozantinib, perhaps because their tumors have a genetic mutation that makes the cells more susceptible to killing by cabozantinib.

If you go back and look at the trial data for Bristol-Myers Squibb (NYSE: BMY  ) and Eli Lilly's (NYSE: LLY  ) Erbitux and Amgen's (Nasdaq: AMGN  ) Vectibix you'd find outliers on the other side -- those that didn't respond well to the treatment because they had a mutation in KRAS, which renders the drugs ineffective.

Having outliers in the cabozantinib arm is an interesting scientific puzzle that I'm sure Exelixis will follow up on, but it shouldn't affect the approval. Both Erbitux and Vectibix were approved, and then their labels were subsequently changed when the scientific discovery was made.

If the outliers are in the placebo group only, that could potentially spell trouble for an approval.

Placebo controlled trials are only accurate if the patients are evenly balanced between the two groups. Things like age and gender have to be controlled for in each trial, and then there are factors for each disease. Diabetes drug makers like MannKind (Nasdaq: MNKD  ) and Amylin Pharmaceuticals (Nasdaq: AMLN  ) for instance, have to match up the HbA1c levels to ensure there are similar HbA1c levels across the treatment groups.

The Food and Drug Administration could argue that having outliers only in the placebo group implies that the trial wasn't balanced. Of course the outliers landing in just the placebo group could have happened randomly as well, but then we're getting well beyond third-grade math.

Until we see the full data it's hard to handicap the risk of the FDA might balk, but I'd guess it's fairly low. First, there's a good chance that it can be explained by a response to cabozantinib, but even if the outliers were only in the placebo arm, it may not be the end of the world. There aren't any drugs approved to treat medullary thyroid cancer patients this late in progression -- AstraZeneca's (NYSE: AZN  ) vandetanib is approved for earlier use -- and the FDA tends to be more lenient with drugs for unmet medical needs.

It's Almost Time to Buy ? A sudden correction and hyper volatility have spooked investors. This is fantastic news. A once-in-a-generation buying opportunity is at hand. Do you know exactly what to buy and how much? Here's a solution.

Follow along as a former hedge fund manager actively manages a $1 million stock portfolio in real time. This is the first and ONLY opportunity this year, by invitation only. Claim your no-obligation invitation ? plus a never-seen report revealing "5 Handpicked Stocks for the Coming Bull Market." It's free to individual investors for a limited time. Enter your email address in the box below and click the button now.

Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement

Source: http://feeds.fool.com/~r/usmf/foolwatch/~3/NzQRAVZJ2FY/biotech-blunder-turned-20-overnight-gain.aspx

consumer debt settlement consumer debt solutions credit card debt advice credit card debt collection

Why Debt Settlement Could Possibly Be Best Approach To Get Out Of Considerable Credit Card Debt

If you are striving to help make your minimum amount installment payments on the huge consumer debt you could grant a debt negotiation program a peek. It could be the most effective solution that you are in need of. For many, it’s the recommended consumer debt fix you can find. Credit card debt negotiation can [...]

Source: http://www.legaldebthelponline.com/2011/10/28/why-debt-settlement-could-possibly-be-best-approach-to-get-out-of-considerable-credit-card-debt/

debt iva debt lawyer debt management group debt management software

Wipe Out Past Due Accounts When You Hire Debt Collection Services For The Job

[WizardRSS: unable to retrieve full-text content]

When your company has failed to collect from overdue customers, it is time for a debt collection agency to step into the picture. Getting back monies owed to your company is now possible once you hire a firm that knows how.

Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement

Source: http://ezinearticles.com/6648486

debt consolidation canada debt consolidation florida debt consolidation leads debt consolidation lenders

The Credit Card Valve Is NOT Easy to Control

[WizardRSS: unable to retrieve full-text content]

As a result of these challenging economic times, many Americans exceed their credit card's maximum line of credit thus triggering the default 29.9% interest rate inflaming an already daunting financial problem. Most credit card companies take no responsibility because they believe the card holder has fallen into a trap largely of their own making. At least when the mob was in the loan shark business, their victims didn't have to put up with that kind of self-righteous nonsense. This article details how the banks and credit card companies prey on the poorest of us and offers simple strategies on avoiding this almost criminal act.

Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement

Source: http://ezinearticles.com/6652611

military debt consolidation moorcroft debt recovery negotiating credit card debt non profit debt help

Consolidating Debts

Significant credit card debt is not unusual today with many individuals carrying credit card debt of $9,500 on average. Interest rates may be as high as 25%, so you might want to consider debt management and debt consolidation services. With debt consolidation, you consolidate all your debts into a single loan. There is also a [...]

Source: http://www.legaldebthelponline.com/2011/10/22/consolidating-debts/

american credit card debt american debt relief american debt settlement american debt solutions